Evidence map›Paper›PMID 42307959›Full record

ArticleJAMA surgery2026

Specimen PET-CT Imaging for Intraoperative Margin Assessment in Early-Stage Breast Cancer: The BrIMA Nonrandomized Clinical Trial.

Menekse Göker, Markus Hahn, Ximena Elzo Kraemer, Hakima Harrach, Marian Vanhoeij, Glenn Vergauwen, Koen Van de Vijver, Kathia De Man, Fabian Schmidt, Selin Guergan and 4 more

Registry-linked trialAbstract readControlled Clinical TrialMulticenter Study
In one paragraph

Article in JAMA surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04999917 (High-resolution PET-CT Imaging for Intraoperative Margin Assessment in Early-stage Breast Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04999917 nacompletednot on this map

High-resolution PET-CT Imaging for Intraoperative Margin Assessment in Early-stage Breast Cancer: a Prospective Multicentric Interventional Clinical Study

TypeinterventionalSponsorXEOS MedicalRan2022 to 2025Enrolled206ConditionsBreast Cancer, Breast Cancer Invasive, Breast Cancer in SituArmshigh-resolution PET-CT specimen imaging.
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Menekse GökerDepartment of Obstetrics and Gynecology, Ghent University Hospital, Ghent, Belgium.
Markus HahnDepartment of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Ximena Elzo KraemerIntegrated Cancer Center Ghent, Department of Medical Oncology, Maria Middelares Hospital, Ghent, Belgium.
Hakima HarrachInterdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany.
Marian VanhoeijDepartment of Oncological, Thoracic and Transplant Surgery, UZ Brussel (University Hospital Brussels), Brussels, Belgium.
Glenn VergauwenDepartment of Obstetrics and Gynecology, Ghent University Hospital, Ghent, Belgium.
Koen Van de VijverCancer Research Institute Ghent, Ghent, Belgium.
Kathia De ManDepartment of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Fabian SchmidtDepartment of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Selin GuerganDepartment of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Valérie VerguchtDepartment of General Surgery, Maria Middelares Hospital, Ghent, Belgium.
Rosa Di MiccoBreast Surgery Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
Giovanni CisterninoBreast Surgery Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
Oreste Davide GentiliniBreast Surgery Unit, IRCCS Ospedale San Raffaele, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Positive margins occur in 12% to 30% of breast-conserving surgeries and are associated with increased local recurrence risks. Accurate and efficient intraoperative margin assessment, therefore, remains an unmet clinical need. Objective: To evaluate the success rate of intraoperative specimen positron emission tomography (PET)-computed tomography (CT) imaging in addressing positive margins in patients with invasive ductal carcinoma. Design, Setting, and Participants: This was an interventional, multicenter, nonrandomized clinical trial that recruited patients from June 2022 to March 2025. Patients were followed up 2 weeks after surgery. Six European breast cancer centers participated and integrated specimen PET-CT imaging into their routine surgical flow. The analysis included eligible patients with early-stage breast cancer scheduled for breast-conserving surgery. Interventions: Patients received an intravenous injection of low-dose 18F-fluorodeoxyglucose (FDG; 0.8 MBq/kg). After tumor excision, the specimen was imaged intraoperatively using a dedicated specimen PET-CT scanner. Surgeons interpreted PET-CT images intraoperatively, and additional tissue was excised when margins were deemed suspicious to achieve final negative margins. Main Outcomes and Measures: The primary outcome was the success rate of specimen PET-CT in addressing positive margins for the invasive component in patients undergoing breast-conserving surgery for invasive ductal carcinoma. Secondary outcomes included success rates in other breast cancer subtypes, final positive margin rates, reoperation rates, and diagnostic performance using histopathology as the reference standard. Results: The analysis cohort consisted of 148 female patients with a median (IQR) age of 65 (53-73) years and a median (IQR) preoperative tumor size of 17 (12-22) mm. For the invasive component of invasive ductal carcinoma, success rates increased from 83.3% (70 of 84 patients) without intraoperative margin assessment (IMA) to 86.9% (73 of 84 patients) with routine margin assessment and to 95.2% (80 of 84 patients) with specimen PET-CT (P < .001 vs no IMA). Across all study groups, success rates improved from 76.4% (113 of 148 patients) without IMA to 81.8% (121 of 148 patients) with routine margin assessment techniques and to 91.9% (136 of 148 patients) with specimen PET-CT (P < .001 vs no IMA; P = .009 vs standard-of-care IMA). Conclusions and Relevance: Study findings show that specimen PET-CT imaging was associated with an improvement in the assessment of positive margins for invasive component in patients undergoing conserving surgery for early breast cancer. The use of this integrated approach might lead to a substantial reduction of re-excision rates after breast-conserving surgery. Trial Registration: ClinicalTrials.gov Identifier: NCT04999917.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastMargins of ExcisionMastectomy, SegmentalPositron Emission Tomography Computed TomographyAgedFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoplasm StagingRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID42307959
PMCPMC13276671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.